Prof. Fabrice Barlesi has been appointed as chief executive officer of Gustave Roussy for a term of 5 years. Prof. Barlesi has been medical director and clinical research director there since January of 2020. Prior to that Prof. Barlesi was professor of medicine at the University of Aix-Marseille and was the head of the Multidisciplinary Oncology and Innovative Therapies department and the Marseille Centre for Early Trials in Oncology at the Assistance Publique Hôpitaux de Marseille. In addition, he is the co-founder of the Marseille Immunopole, a French Immunology network, and he previously served as the vice-chair of the Provence, Alps and Côte d’Azur (PACA) Region Cancer Research Directorate. Prof. Barlesi coordinated the French Thoracic Intergroup (IFCT) Biomarkers France study, which, with more than 18,000 patients, is still one of the largest molecular profiling study on patients with lung cancer. He is also coordinating the PIONeeR project, a €25 million-project dedicated to the understanding and bypass of resistances to PD-(L)1 inhibitors in patients with lung cancer.
Serving as an Associate Editor for ILCN since its inception, Prof Barlesi also is this year’s recipient of the IASCL’s Daniel C. Ihde Lectureship Award for Medical Oncology and was the 2018 recipient of the Heine H. Hansen award from the European Society for Medical Oncology.
